Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.72 |
| ▸ | FNTB | P49356 | 7/20 | 0.72 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.56 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311793 | 0.88 | FNTA (0.81) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL14722419 | 0.87 | FNTA (0.80) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL1312201 | 0.87 | FNTA (0.58) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL2162004 | 0.86 | FNTA (0.78) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL4736266 | 0.86 | FNTA (0.78) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL1310943 | 0.85 | FNTA (0.74) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL2162288 | 0.85 | FNTA (0.74) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL2162264 | 0.85 | FNTA (0.77) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL17817386 | 0.84 | FNTA (1.00) | FNTAFNTBSRD5A1SRD5A2NPC1L1 | |
| SCHEMBL2161763 | 0.84 | FNTA (1.00) | FNTAFNTBSRD5A1SRD5A2NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163934-A1 | BBB-PASSING LIPID LIGAND OF HETERO NUCLEIC ACID | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163934-A1 | BBB-PASSING LIPID LIGAND OF HETERO NUCLEIC ACID | LDLR, FABP7, APOB | FNTA 1036/4885FNTB 561/4885SRD5A1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.